Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.35 GBX | 0.00% | -2.90% | -43.22% |
04-22 | Valirx plc Announces Directorate Changes | CI |
03-21 | ValiRx inks evaluation deal with Imperial College London for research | AN |
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 4.43M 5.57M 7.61M |
---|---|---|---|---|---|
Net income 2023 * | -2M -2.51M -3.43M | Net income 2024 * | - | EV / Sales 2023 * | - |
Net cash position 2023 * | 1.8M 2.26M 3.09M | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.02
x | P/E ratio 2024 * |
-
| Employees | 8 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 83.27% |
1 week | -2.90% | ||
Current month | -5.63% | ||
1 month | -4.96% | ||
3 months | -32.32% | ||
6 months | -63.78% | ||
Current year | -43.22% |
Managers | Title | Age | Since |
---|---|---|---|
Suzanne Dilly
CEO | Chief Executive Officer | 46 | - |
Gerald Desler
DFI | Director of Finance/CFO | 79 | 06-08-31 |
Chief Tech/Sci/R&D Officer | - | 22-09-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Desler
DFI | Director of Finance/CFO | 79 | 06-08-31 |
Kevin Cox
CHM | Chairman | 65 | 20-06-25 |
Director/Board Member | 57 | 02-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 3.35 | 0.00% | 154 406 |
24-04-26 | 3.35 | +1.52% | 164,059 |
24-04-25 | 3.3 | -4.35% | 607,805 |
24-04-24 | 3.45 | 0.00% | 49,024 |
24-04-23 | 3.45 | 0.00% | 1,232,579 |
Delayed Quote London S.E., April 29, 2024 at 11:35 am
More quotesChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-43.22% | 5.52M | |
-2.87% | 103B | |
+1.57% | 95.28B | |
+1.46% | 22.15B | |
-16.19% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.26% | 16.05B | |
+5.65% | 13.68B | |
+33.28% | 12.17B |
- Stock Market
- Equities
- VAL Stock